We are live on ! Find out more
PETX

Aratana Therapeutics, Inc.
PETX

Delisted

PETX was delisted on the 17th of July, 2019.

87 hedge funds and large institutions have $510M invested in Aratana Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 20 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

88% more first-time investments, than exits

New positions opened: 15 | Existing positions closed: 8

85% more capital invested

Capital invested by funds: $276M → $510M (+$234M)

80% more repeat investments, than reductions

Existing positions increased: 36 | Existing positions reduced: 20

6% more funds holding

Funds holding: 8287 (+5)

Holders
87
Holders Change
+5
Holders Change %
+6.1%
% of All Funds
2.32%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
15
Increased
36
Reduced
20
Closed
8
Calls
$188K
Puts
Net Calls
+$188K
Net Calls Change
+$193K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$65.4M -$1.01M -81,147 -2%
Franklin Resources
2
Franklin Resources
California
$59.2M -$560K -44,913 -1%
Jennison Associates
3
Jennison Associates
New York
$55.8M +$722K +57,943 +2%
MAM
4
MPM Asset Management
Massachusetts
$37.8M
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$23.2M -$3.43M -275,000 -17%
BC
6
Broadfin Capital
New York
$22.4M -$2.28M -182,964 -13%
BFA
7
BlackRock Fund Advisors
California
$21.5M +$6.6M +529,960 +78%
Massachusetts Financial Services
8
Massachusetts Financial Services
Massachusetts
$19.8M -$1.7M -136,091 -11%
AllianceBernstein
9
AllianceBernstein
Tennessee
$19.7M -$881K -70,728 -6%
Vanguard Group
10
Vanguard Group
Pennsylvania
$15M +$1.35M +108,605 +15%
Lazard Asset Management
11
Lazard Asset Management
New York
$14.7M +$6.55M +525,410 +174%
D.E. Shaw & Co
12
D.E. Shaw & Co
New York
$12.1M +$132K +10,626 +2%
AIC
13
AWM Investment Company
New York
$10.7M +$7.48M +600,000 New
CCI
14
Columbus Circle Investors
$9.57M +$6.69M +537,019 New
O
15
OppenheimerFunds
New York
$9.46M +$915K +73,433 +16%
VAM
16
Visium Asset Management
New York
$6.68M +$2.74M +220,000 +142%
BIT
17
BlackRock Institutional Trust
California
$6.44M +$950K +76,234 +27%
State Street
18
State Street
Massachusetts
$6.17M +$517K +41,516 +14%
JP Morgan Chase
19
JP Morgan Chase
New York
$5.95M -$3.15M -252,927 -43%
SCM
20
Sio Capital Management
New York
$5.8M +$4.05M +325,420 New
Northern Trust
21
Northern Trust
Illinois
$5.38M +$451K +36,210 +14%
Goldman Sachs
22
Goldman Sachs
New York
$5.23M -$304K -24,363 -8%
HHC
23
Hutchin Hill Capital
New York
$4.46M +$779K +62,500 +33%
William Blair & Company
24
William Blair & Company
Illinois
$4.43M +$1.15M +92,625 +59%
Principal Financial Group
25
Principal Financial Group
Iowa
$4.19M -$130K -10,400 -4%

PETX Hedge Fund Activity: Q4 2014 in Review

87 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Aratana Therapeutics, Inc. (PETX) for Q4 2014, worth a combined $510M — up 85% from $276M a quarter earlier.

Buyers outnumbered sellers: 15 funds opened new PETX positions and 8 closed out — a net gain of 7 holders — while 36 added to existing stakes and 20 trimmed.

The largest buyer was Columbus Circle Investors, opening a new position worth an estimated $6.69M. The largest seller was Highland Capital Management (Texas), cutting an estimated $5.56M.

  • 87 institutional investors held Aratana Therapeutics, Inc. (PETX) as of Q4 2014, up from 82 in Q3 2014.
  • Funds reported $510M of Aratana Therapeutics, Inc. stock for Q4 2014, up 85% quarter-over-quarter.
  • 15 funds opened new Aratana Therapeutics, Inc. positions in Q4 2014 and 8 closed out, a net change of +7 holders.
  • The largest Aratana Therapeutics, Inc. buyer in Q4 2014 was Columbus Circle Investors, an estimated $6.69M added.
  • The largest Aratana Therapeutics, Inc. seller in Q4 2014 was Highland Capital Management (Texas), an estimated $5.56M sold.

Based on aggregated 13F filings for Q4 2014.